-

BIO Appoints New CFO

Steve Jasko will Succeed Highly Respected Yvette White Wiggins

WASHINGTON--(BUSINESS WIRE)--The Biotechnology Innovation Organization (BIO) announced today the retirement of Senior Vice President and Chief Financial Officer (CFO), Yvette White-Wiggins, after a distinguished 18-year career with the organization. White-Wiggins rose through the ranks at BIO and served as CFO since 2016, building a solid financial infrastructure that will serve the organization for years to come.

“We are truly grateful for Yvette’s extraordinary service to BIO over her long tenure here,” said Dr. Michelle McMurry-Heath, BIO’s President and CEO. “Yvette’s commitment to our organization went beyond expert cash management and financial accounting. She was a true believer in our mission to improving lives, as she faced her own challenges with two different types of cancer. Her life story continues to be an inspiration to us all.”

A prominent contributor to BIO’s “I am BIO” campaign, White-Wiggins can be seen here moderating the inaugural video in the series.

White-Wiggins will be succeeded by Steve Jasko who brings more than 25 years of financial and operational experience to the position. He has served as CFO for two not-for-profit organizations, the TB Alliance, and Howard Hughes Medical Institute. His pharmaceutical experience includes six years at Celgene where he first held the position of Corporate Treasurer and later Vice President of Finance and Business Development for the Cellular Therapeutics Division. He also has nearly a decade of experience working at Merck.

“As BIO moves into its next chapter, we welcome Steve to the team,” said McMurry-Heath. “His wide range of financial experience as well as his background in non-profits and pharmaceutical companies will make this a smooth transition. We look forward to his building on the foundation that Yvette built.”

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Biotechnology Innovation Organization


Release Versions

More News From Biotechnology Innovation Organization

New Strategic Vision for Biotechnology Innovation Organization

WASHINGTON--(BUSINESS WIRE)--The Biotechnology Innovation Organization (BIO) today announced a new, strategic direction that will help guide it to achieving long-term goals while maintaining responsiveness to changing political headwinds. Announcing the new vision, mission and purpose to member companies, BIO’s recently appointed President and CEO, Dr. Michelle McMurry-Heath remarked, “We need to be the face and the voice of science—speaking up for the millions of families around the globe who...

North Carolina Governor Roy Cooper Named BIO’s Governor of the Year

WASHINGTON--(BUSINESS WIRE)--Today, the Biotechnology Innovation Organization awarded Roy Cooper, Governor of North Carolina, with its 2020 Governor of the Year Award. Governor Cooper was presented the award virtually at NCBIO’s 2020 Annual Meeting. BIO’s annual award recognizes governors for leadership in public service, commitment to public health, and dedication to advancing biotechnology in their state. “Innovations in life sciences are transforming the way we approach treating diseases, en...

Gov. Hogan, Novavax’ Erck, & BIO’s Dr. McMurry-Heath Toured Novavax Labs and Discussed Progress on COVID-19 Vaccine

GAITHERSBURG, Md.--(BUSINESS WIRE)--Today, Maryland Governor Larry Hogan and Dr. Michelle McMurry-Heath, President & CEO of Biotechnology Innovation Organization (BIO), joined Novavax President & CEO Stanley Erck to discuss the importance of the biotechnology sector in Maryland, the industry’s efforts to address COVID-19, and progress being made by Novavax to develop a vaccine for the deadly virus. A video of the remarks is now available. "When the COVID-19 crisis began, even before we...
Back to Newsroom